Bone Biologics (BBLG) Expected to Announce Quarterly Earnings on Wednesday

Posted by ABMN Staff on Feb 18th, 2026

Bone Biologics (NASDAQ:BBLG – Get Free Report) is anticipated to release its results before the market opens on Wednesday, February 25th. Analysts expect Bone Biologics to post earnings of ($0.34) per share for the quarter.

Bone Biologics Price Performance

Shares of BBLG opened at $1.12 on Wednesday. The stock has a market capitalization of $2.02 million, a PE ratio of -0.31 and a beta of 0.75. The business’s fifty day moving average price is $1.64 and its 200 day moving average price is $1.96. Bone Biologics has a 12-month low of $1.11 and a 12-month high of $7.50.

Institutional Investors Weigh In On Bone Biologics

A hedge fund recently raised its stake in Bone Biologics stock. DRW Securities LLC grew its position in shares of Bone Biologics Corp. (NASDAQ:BBLG – Free Report) by 113.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 23,576 shares of the company’s stock after acquiring an additional 12,549 shares during the quarter. DRW Securities LLC owned about 1.31% of Bone Biologics worth $34,000 as of its most recent filing with the SEC. 34.30% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e)” rating on shares of Bone Biologics in a research report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Get Our Latest Stock Report on Bone Biologics

About Bone Biologics

(Get Free Report)

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.